Mayo Clinic researchers completed a study in Modern Pathology to examine ERBB2 amplification and protein expression in micropapillary urothelial carcinoma and stage-matched typical urothelial carcinoma treated by radical cystectomy to assess the frequency of amplification and protein expression, and to determine the association with cancer-specific survival. Read this post to learn more.
The new RAS/RAF Targeted Gene Panel by Next Generation Sequencing, Tumor, test is now available to the Mayo Clinic practice and Mayo Medical Laboratories clients. In this post, Dr. Ande Rumilla discusses the clinical significance, proper ordering scenarios, and the science behind the test.
According to a recent Mayo Clinic-led study, most patients with triple-negative breast cancer should undergo genetic testing for mutations in known breast cancer predisposition genes, including BRCA1 and BRCA2. The findings come from the largest analysis to date of genetic mutations in this aggressive form of breast cancer.
Mayo Clinic Study Finds Chromosomal Rearrangements Help Distinguish Between Independent Primary Tumors and Metastasis
GenomeDx, Mayo Clinic to Conduct Validation Study of Decipher® Prostate Cancer Test
Mayo Clinic Pathologists Decrease Need for Repeat Surgeries
Cologuard Receives FDA Approval
CAP TODAY: “Unraveling Metastasis With Circulating Tumor Cells”